文献速递腹部介入US

组织碎裂术治疗肝细胞癌:从基础到临床

Histotripsy for Hepatocellular Carcinoma: From Bench to Bedside.
PubMed 文献 · Radiology · 2026-01-01

本文综述了组织碎裂术治疗肝细胞癌从临床前研究到FDA批准的过程。组织碎裂术是一种非侵入性聚焦超声消融技术,通过声空化机械性破坏肿瘤而非热效应。

要点

  • 组织碎裂术通过声空化机械破坏肿瘤,保留血管和胆管结构,适用于热消融受热沉效应影响的血管周围病变。
  • 临床证据支持对3cm及以下肿瘤效果最佳,技术成功率约95%,1年局部控制率约90%。
  • 临床前研究观察到消融后免疫细胞浸润,提示可能具有远隔效应,正在探索与免疫治疗联用。

核心结论

  • 组织碎裂术是一种非侵入性聚焦超声消融技术,通过声空化机械性液化靶组织,代表局部消融的范式转变。
  • 组织碎裂术在保留血管和胆管等关键结构的同时实现精准机械性组织碎裂,临床证据显示约95%技术成功率和约90%的1年局部控制率。

研究设计与样本

  • 本文为综述,梳理了组织碎裂术从临床前发展到FDA批准治疗肝脏肿瘤的全过程。
  • 临床证据来源于THERESA和#HOPE4LIVER等临床试验。
  • 技术原理涉及使用短时高压超声脉冲产生空化气泡云来液化靶组织。

关键影像表现/征象

  • 组织碎裂术形成精准的机械性组织碎裂,而非热消融的凝固性坏死。
  • 治疗过程中血管和胆管等关键结构得以保留。

诊断标准与关键数值

  • 临床证据支持对3cm或更小的肿瘤获得最佳疗效。
  • #HOPE4LIVER试验显示技术成功率约95%,1年局部控制率约90%。

临床应用与阅片要点

  • 组织碎裂术适合血管周围病变,因不受热沉效应影响。
  • 病例选择方面,3cm及以下肿瘤是当前证据支持的最佳适用人群。
  • 影像报告中应关注治疗后组织液化的机械性碎裂表现,并评估残余灌注。

局限性

  • 原文仅报告了短期疗效数据,长期结果仍有待观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality, with limited curative options. Histotripsy is a noninvasive focused ultrasound ablation technique that destroys tumors through acoustic cavitation rather than heat-based methods, offering an alternative to radiofrequency and microwave ablation. This review traces histotripsy from preclinical development to U.S. Food and Drug Administration (FDA) approval for liver tumors. Unlike thermal methods, histotripsy creates precise mechanical tissue fractionation while preserving critical structures, including blood vessels and bile ducts. The technology uses short, high-pressure ultrasound pulses to generate cavitation bubble clouds that liquefy targeted tissue without thermal damage. Preclinical studies demonstrated complete tumor ablation with robust immune cell infiltration, suggesting potential abscopal effects. Clinical trials, including THERESA and #HOPE4LIVER, confirmed safety, with #HOPE4LIVER demonstrating short-term efficacy, achieving approximately 95% technical success and approximately 90% 1-year local control rates. Histotripsy received FDA approval in October 2023 for treating liver cancer. The technology shows promise for perivascular lesions where heat-sink effects compromise thermal ablation. Current evidence supports optimal outcomes for tumors 3 cm or smaller, with ongoing research exploring combinations with immunotherapy and applications beyond HCC. Histotripsy represents a paradigm shift in local ablation, offering mechanical precision combined with potential systemic immunostimulatory benefits. © The Author(s) 2026. Published by the Radiological Society of North America under a CC BY 4.0 license.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Luo, Wei, Lu, et al. Histotripsy for Hepatocellular Carcinoma: From Bench to Bedside. Radiology. 2026. PMID: 42708851. doi:10.1148/radiol.254050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。